New hope for HER2 breast cancer: experimental combo faces standard care in major trial
NCT ID NCT07441460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new combination of drugs (KN026 plus HB1801 and chemotherapy) works better than the current standard treatment (trastuzumab, pertuzumab, and chemo) for people with HER2-positive breast cancer that has been surgically removed. About 1800 adults with cancer spread to lymph nodes will take part. The goal is to see if the new combo delays cancer return or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201318, China
Contact Phone: •••-•••-•••• Email: •••••@•••••